OXYGEN, USP
Peakcarbon dioxide-air mixture
NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OXYGEN, USP (carbon dioxide-air mixture) is x-ray contrast activity [moa]. First approved in 2013.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYGEN, USP is a carbon dioxide-air mixture gas product approved as a radiographic contrast agent administered via inhalation. It functions through x-ray contrast activity to enhance imaging visualization. This product serves diagnostic imaging purposes in clinical settings.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable team sizing but potential for strategic repositioning initiatives.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product currently shows zero linked job openings, indicating a mature, stable franchise with limited hiring activity. Roles on OXYGEN, USP focus on maintaining market position and managing physician relationships in the diagnostic imaging space.
Medical Science LiaisonBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.